image: The University of Copenhagen is excited to announce Immortal Dragons as Tier 4 Sponsor of the 12th Aging Research & Drug Discovery Meeting
Credit: ARDD
The University of Copenhagen is excited to announce Immortal Dragons as Tier 4 Sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online.
Immortal Dragons is a purpose-driven longevity fund headquartered in Singapore, supporting 15+ portfolio companies in longevity and radical life extension technologies. Immortal Dragons values impact rather than economic return, supporting moonshot longevity startups in radical life extension, key areas include: Wholebody replacement, 3D bioprinting, Gene therapy, Special economic zone, Longbio fund. Beyond investment, the fund actively supports the ecosystem through longevity welfare grants, conference sponsorships, book translations & publishing and hosting leading chinese longevity podcast.
Topics Immortal Dragons may be addressing:
-Impact over return: longevity needs breakthroughs and advocation. In Immortal Dragons, we are doing lots of evangelism work to raise public awareness, and supporting cutting-edge science with huge potential and less return likelihood.
-Replace not Repair: Immortal Dragons' investment thesis is built around this concept, where we disagree with the inevitability of againg, and consider part replacement as one of the promising directions to solve againg rather than repairing exisiting flaws.
“I’ve never reconciled with the idea that aging and death are inevitable or that we should accept the suffering that comes with age-related diseases,” says Boyang, Founder of Immortal Dragons, "the challenges of aging and disease are engineering problems that humanity can and must overcome, we are delighted to be supporting ARDD 2025 as we overcoming the challenge." said Boyang Wang, Immortal Dragon's Founder.
ARDD has grown to become the largest and most important conference in longevity biotechnology. Each year, ARDD brings together a unique mix of academic luminaries, biotech innovators, investors, top pharmaceutical executives, physicians, and related health care professionals to discuss the latest advancements in aging research and the event provides unique opportunities to connect with brilliant minds, fostering collaboration and showcasing groundbreaking research in the field.
“We are extremely honored to host Professors Meldal and Levitt at ARDD2025. Their Nobel prize winning discoveries have been instrumental for drug development and molecular design in part through modelling of proteins and molecules, and in part through the ability to easily create new molecules. It is therefore a great pleasure that they are joining our conference.” said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
“We are really excited for ARDD2025, especially with Nobel Laureates Morten Meldal and Michael Levitt joining us. Their groundbreaking contributions have had a lasting impact on drug discovery, and having them at the conference is sure to make it an unforgettable experience.” said Daniela Bakula, Ph.D., University of Copenhagen.
“For 12 years, the Aging Research and Drug Discovery (ARDD) forum grew in size and in quality. It became the world’s main platform for academia-pharma-startup-investor partnership and dialogue. In 2025, the conference will feature the Nobel laureates, pharmaceutical industry executives and healthcare delivery leaders. ARDD is a unique platform for advancing longevity biotechnology around the world.” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine.
“At ARDD we strive to highlight the cutting-edge research and clinical applications in a new discipline of healthy longevity medicine. Having Nobel laureates join and speak at the ARDD conference underscores the critical importance of grounding longevity science and medicine in evidence-based, scientifically rigorous approaches.” said Prof.Dr.Evelyne Bischof, the organizer of the Longevity Medicine Days.
Aging research has become a great platform for advancing drug discovery with blockbuster potential, with pharmaceutical leaders like Novartis, Biogen, and Eli Lilly actively supporting this transformative field. ARDD has established itself as the go-to venue where scientists and pharma companies collaborate, share insights, and launch aging-focused research initiatives. In 2024, industry leaders such as Eli Lilly, Novartis, Regeneron, Biogen, and Lundbeck presented their latest research at ARDD, highlighting the meeting's pivotal role in advancing healthspan and longevity science. Be part of ARDD 2025 and contribute to shaping the future of medicine.
For further information, images or interviews, please contact:
ardd@pharma.ai
About Aging Research for Drug Discovery Conference
At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we will have a special day called Longevity Medicine Day, specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. Our quest to extend the healthy lifespan of everyone on the planet.